Want to apply for Canada PR? The country is set to introduce four new permanent residency (PR) pathways in 2025, even as the government plans to reduce its PR targets from 485,000 to 465,000, ...

The world’s richest man raised plenty of eyebrows when he flung his arm up during a post-inauguration rally in Washington, but his supporters say he’s just awkward. Breaking News Reporter ...

The Hubble tension grows: new data shows the Universe’s expansion defies current physics models, suggesting our understanding of cosmology may need a major overhaul. Credit: SciTechDaily.com New ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Last year, the CMS Innovation Center launched the Quality Pathway strategic initiative to strengthen the focus on quality in alternative payment models. Since it was created, the CMS Innovation ...

By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Libtayo has been approved by regulatory authorities in more than 30 ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Libtayo is designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation and already holds approvals to treat certain patients with advanced CSCC. C-POST met its primary ...